Stephen Sherwin

Stephen Sherwin

Directeur/Membre du Conseil chez BIOPLUS ACQUISITION CORP.

Fortune : 7 M $ au 30/04/2024

75 ans
Health Technology
Consumer Services
Finance

Profil

Stephen A.
Sherwin
was the founder of Ceregene, Inc. (founded in 2001) where he served as Chairman from 2001 to 2013.
He is also the founder of Abgenix, Inc. Dr. Sherwin's current job positions include Lead Independent Director at Neurocrine Biosciences, Inc. (since 1999), Independent Director at Biogen, Inc. (since 2010), Director at Avertix Medical Systems, Inc., Director at Rheos Medicines, Inc., Independent Director at BioPlus Acquisition Corp.
(since 2021), Professor at The University of California, San Francisco, Member of the American Society of Clinical Oncology, Inc., Member of the American Association for Cancer Research, Advisory partner at Third Rock Ventures LLC (since 2016), Member-Supervisory Board at Biogen GmbH (since 2010), and Clinical Professor at the University of California.
Dr. Sherwin's former job positions include Chairman & Chief Executive Officer at Cell Genesys, Inc. (1990-2009), Chairman at Biotechnology Innovation Organization (2001-2014), Independent Director at Vical, Inc. (2013-2015), Director at ANI Pharmaceuticals, Inc. (2009-2013), Independent Director at Rigel Pharmaceuticals, Inc. (2000-2017), Independent Director at Aduro BioTech, Inc. (2015-2020), Director at Biogen Idec New Ventures, Inc., Independent Director at Verastem, Inc. (2013-2016), Independent Director at BioNTech US, Inc. (2015-2020), and Vice President-Clinical Research at Genentech, Inc. (1983-1990).
Dr. Sherwin's education includes an undergraduate degree from Yale University and a doctorate degree from Harvard Medical School.
Dr. Sherwin is also the founder of Abgenix, Inc...

Détentions connues dans des sociétés publiques

SociétéDateNombre d'actionsValorisationDate de valorisation
29/05/2024 26 504 ( 0,03% ) 4 M $ 30/04/2024
22/04/2024 17 778 ( 0,01% ) 4 M $ 30/04/2024

Postes actifs de Stephen Sherwin

SociétésPosteDébut
BIOGEN INC. Directeur/Membre du Conseil 01/01/2010
NEUROCRINE BIOSCIENCES, INC. Directeur/Membre du Conseil 01/04/1999
BIOPLUS ACQUISITION CORP. Directeur/Membre du Conseil 01/12/2021
Consultant / Advisor 01/01/2016
University of California Corporate Officer/Principal -
Directeur/Membre du Conseil 01/01/2010
Directeur/Membre du Conseil -
Corporate Officer/Principal -
The University of California, San Francisco Corporate Officer/Principal -
░░░░░░░░ ░░░░░░░ ░░ ░░░░░░░░ ░░░░░░░░░ ░░░░ ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
Tous les postes actifs de Stephen Sherwin

Anciens postes connus de Stephen Sherwin

SociétésPosteFin
░░░░░░░ ░░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ ░░░░░░░░░░
░░░░ ░░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ ░░░░░░░░░░
░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ ░░░░░░░░░░
░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ ░░░░░░░░░░
░░░░░░ ░░░░ ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ ░░░░░░░░░░
Voir l'expérience en détail de Stephen Sherwin

Formation de Stephen Sherwin

Yale University Undergraduate Degree
Harvard Medical School Doctorate Degree

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Voir l'expérience en détail de Stephen Sherwin

Relations

100 +

Relations au 1er degré

26

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Voir le réseau personnel

Sociétés liées

Sociétés cotées5
ANI PHARMACEUTICALS, INC.

Health Technology

BIOGEN INC.

Health Technology

NEUROCRINE BIOSCIENCES, INC.

Health Technology

RIGEL PHARMACEUTICALS, INC.

Health Technology

VERASTEM, INC.

Health Technology

Entreprise privées17

Health Technology

Health Technology

Health Technology

Commercial Services

Health Services

Finance

Health Technology

Health Technology

Commercial Services

Health Technology

Health Technology

Health Technology

Health Technology

Finance

Finance

Finance

Distribution Services

Voir les connexions sociétés
  1. Bourse
  2. Insiders
  3. Stephen Sherwin
-40% Offre à Durée Limitée : Nos abonnements vous guident vers les meilleurs investissements de demain.
PROFITEZ-EN MAINTENANT